Cargando…
Does clinical method mask significant VTE-related mortality and morbidity in malignant disease?
After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is still limited. Limitations can be related to the...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714244/ https://www.ncbi.nlm.nih.gov/pubmed/19491905 http://dx.doi.org/10.1038/sj.bjc.6605091 |
_version_ | 1782169656237228032 |
---|---|
author | Maraveyas, A Johnson, M |
author_facet | Maraveyas, A Johnson, M |
author_sort | Maraveyas, A |
collection | PubMed |
description | After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is still limited. Limitations can be related to the thromboembolism itself, the underlying cancer, or to the management process. There is significant literature that deals with the first two, but very little regarding the systems we use, or how the inadequacies in documentation, identification and classification of VTE affect the cancer patients themselves. This review aims to raise awareness of this neglected area and stimulate research that may lead to improvements in patient care. |
format | Text |
id | pubmed-2714244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27142442010-06-16 Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? Maraveyas, A Johnson, M Br J Cancer Minireview After more than 150 years of a recognised link between cancer and vascular thromboembolic events (VTE), and despite a greatly improved understanding of its pathophysiology, epidemiology and treatment, the management of patients with cancer and VTE is still limited. Limitations can be related to the thromboembolism itself, the underlying cancer, or to the management process. There is significant literature that deals with the first two, but very little regarding the systems we use, or how the inadequacies in documentation, identification and classification of VTE affect the cancer patients themselves. This review aims to raise awareness of this neglected area and stimulate research that may lead to improvements in patient care. Nature Publishing Group 2009-06-16 2009-06-02 /pmc/articles/PMC2714244/ /pubmed/19491905 http://dx.doi.org/10.1038/sj.bjc.6605091 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Minireview Maraveyas, A Johnson, M Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? |
title | Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? |
title_full | Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? |
title_fullStr | Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? |
title_full_unstemmed | Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? |
title_short | Does clinical method mask significant VTE-related mortality and morbidity in malignant disease? |
title_sort | does clinical method mask significant vte-related mortality and morbidity in malignant disease? |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2714244/ https://www.ncbi.nlm.nih.gov/pubmed/19491905 http://dx.doi.org/10.1038/sj.bjc.6605091 |
work_keys_str_mv | AT maraveyasa doesclinicalmethodmasksignificantvterelatedmortalityandmorbidityinmalignantdisease AT johnsonm doesclinicalmethodmasksignificantvterelatedmortalityandmorbidityinmalignantdisease |